The cost-effectiveness of vaccinating chronic hepatitis C patients against hepatitis A

American Journal of Gastroenterology

Volumn 97, Issue 2, 2002, Pages 427-434

  Jacobs, R Jake ^a,c   Koff, Raymond S ^b   Meyerhoff, Allen S ^a  

^a Capitol Outcomes Research   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^c Capitol Outcomes Research Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS VACCINE;

ABSENTEEISM; ADULT; AGED; ARTICLE; CHRONIC HEPATITIS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; HEALTH CARE; HEPATITIS A; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MORBIDITY; MORTALITY; PRIORITY JOURNAL; SCREENING; VACCINATION;

ADULT; AGED; COHORT STUDIES; COST-BENEFIT ANALYSIS; FEMALE; HEALTH CARE COSTS; HEPATITIS A; HEPATITIS A VACCINES; HEPATITIS C, CHRONIC; HUMANS; MALE; MARKOV CHAINS; MIDDLE AGED; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; UNITED STATES; VACCINATION;

EID: 0036175467     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(01)04043-6     Document Type: Article

References (55)

1. Prevention of hepatitis A through active or passive immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
2. Fulminant hepatitis A in intravenous drug users with chronic liver disease
3. Association between chronic liver disease and death from hepatitis A, United States, 1989-1992
4. Association between deaths due to hepatitis A and chronic liver disease, United States, 1981-1997
5. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C
6. Acute hepatitis-A super-infection in HBV carriers, or chronic liver disease related to HBV or HCV
7. Fulminant hepatitis A in patients with chronic liver disease
8. Hepatitis associated with hepatitis A superinfection in patients with chronic hepatitis C
9. Hepatitis associated with hepatitis A superinfection in patients with chronic hepatitis C
10. Hepatitis associated with hepatitis A superinfection in patients with chronic hepatitis C
11. Mortality of hepatitis A I adults with hepatitis C antibodies
12. Acute hepatitis A in patients with chronic hepatitis C
13. An economic analysis of different strategies of immunization against hepatitis A virus in developed countries
14. Cost effectiveness of childhood hepatitis A vaccination in the USA
15. The cost-effectiveness of adolescent hepatitis A vaccination in states with the highest disease rates
16. Cost-effectiveness of hepatitis A vaccination in healthcare workers
17. Cost-effectiveness of hepatitis A vaccination strategies for adults
18. An economic analysis of the uses of hepatitis A vaccine to control community wide epidemics
19. Vaccination of sexually active homosexual men against hepatitis A: Analysis of costs and benefits
20. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994
21. Are HCV-infected individuals candidates for hepatitis A vaccine?
22. The cost-effectiveness of hepatitis A vaccination in patients with chronic hepatitis C
23. Inactivated hepatitis A vaccine: Reactogenicity, immunogenicity, and long-term antibody persistence
24. Duration of protection from clinical hepatitis A disease after vaccination with VAQTA
25. Inactivated hepatitis A vaccine: Long-term antibody persistence
26. The Markov process in medical prognosis
27. Treatment of chronic type B and C hepatitis with interferon alfa: An economic appraisal
28. Underreporting of viral hepatitis
29. The reporting of communicable diseases
30. Prevention of hepatitis A through active or passive immunization: Recommendations of the ACIP
31. Hepatitis A virus in the 20th century USA - Estimated incidence of infection
32. Hepatitis A incidence in Los Angeles County, California: Prime profile for prevention
33. Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease
34. The cost of hepatitis A infections in American adolescents and adults in 1997
35. Preventing acute liver disease in patients with chronic liver disease
36. Global impact of hepatitis A virus infection: Changing patterns
37. Cost-effectiveness analysis
38. Recommendations of the panel on cost-effectiveness in health and medicine
39. How attractive does a new technology have to be to warrant adoption and utilization?
40. Cost-effectiveness of 6 and 12 months of interferon therapy for chronic hepatitis C
41. Estimates of the cost-effectiveness of a single course of interferon-α2b in patients with histologically mild chronic hepatitis C
42. Frequency of illness associated with epidemic hepatitis A virus infections in adults
43. Incidence of hepatitis B virus infection in the United States, 1976-1994: Estimates from the National Health and Nutrition Examination Survey
44. Pertussis hospitalizations and mortality in the United States, 1985-1988. Evaluation of the completeness of national reporting
45. Sources of infection among persons with acute hepatitis A and no identified risk factors during a sustained community-wide outbreak